Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

RESI San Francisco 2020 – Agenda Announced

21 Nov

By Lucy Parkinson, VP of Investor Research, LSN

On January 14th, RESI will be back in San Francisco, and LSN would like to present the panel and workshop agenda.  In addition to the all-new RESI Featured Company Pitch Sessions, RESI SF will feature three tracks of panel and workshop content, and RESI’s industry-leading Partnering from 8am-5pm.

RESI panels feature a moderator and 4 panelists who are experienced investors and industry experts who can guide entrepreneurs on what they need to do to raise capital.  RESI will feature panels focused on specific verticals, such as Early Stage Therapeutics, AI in Healthcare, Oncology Innovation, and an all-new panel on Investing In Life Science Tools.  Other panels focus on key investor groups such as Big Pharma, Corporate Venture Capital, Impact Investors, and Family Offices & Angels.  Additionally, RESI will include a half-day Asia Investors Track from 1.00-5.00pm, in which investors based in the Asia-Pacific region share their strategies on investing in global technology.

RESI’s workshops will include expert presentations on key issues for early stage entrepreneurs, including Company Valuation for Fundraising from Venture Valuation, and Negotiating Term Sheets from McDermott, Will & Emery, and an advice session from experts from the National Institutes of Health.

We hope you can join us during the San Francisco healthcare conference week to take part in this jam-packed agenda.

Life Science Nation’s, Focus on Cures Accelerator (FOC), Now Offering a Fundraising Campaign Curriculum

21 Nov

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN recently launched the Focus on Cures (FOC) Accelerator that helps high-growth, international startup companies move into the global partnering arena through a two-week Boston-based immersion program, titled MKT 466: Funding and Partnering Immersion Course, integrated into LSN’s global partnering network and the RESI conference series. The theme of the FOC accelerator is to create a funnel of elite, top domestic and foreign startups that need to raise angel, seed, series A and B rounds. This course solves an early stage funding challenge: there is no standardized methodology for teaching a company how to brand and message itself and efficiently manage a fundraising campaign. There is no reliable, accurate, and current partner and investor database (besides LSN’s) to get a company a list of global partners that are a fit for their stage of development and product set. Very few entrepreneurs are actually taught how to launch and manage a fundraising campaign, never mind training CEOs how to make an introductory phone call or write an introductory email. Most importantly, no one teaches the holy grail of canvassing for capital, which is, how to follow up.

Participants in the course receive:

  • A year subscription to the LSN investor database, valued at $6,995
  • Branding and messaging collateral for fund raising campaign, (including a logo, tagline, one page data sheet, two page executive summary, and 10-12 slide pitch), valued at $15K
  • A ticket to the next RESI conference to launch the fundraising campaign, valued at $3,000

The course is $10,000 per company, for services valued at $25,000, held at the LSN corporate headquarters in Downtown Crossing, Boston. Each company is expected to send one business and one science executive for the two week immersion class. The first class will be held from May 25th through Jun 5th, leading up to RESI San Diego, taking place on Monday, June 8th.

FOC Accelerator – MKT 466 Funding and Partnering Immersion Course

MKT466 is a unique two-week immersion course designed for life science entrepreneurs to experience the best methodologies for reaching out and establishing a dialogue with partners and  investors, building a relationship and, ultimately, securing capital allocations.

The morning sessions are 3-hour classes teaching the fundamental business development and marketing skills needed to formulate a company theme, create a corporate brand with appropriate messaging and market your firm to investors and strategic partners within the life science arena. (See details in the morning class outline)

The afternoon sessions include 1 hour of meeting the players in the Massachusetts life science ecosystem and 2 hours of curating and reaching out to a list of global investors and channel partners:

  1. Utilize LSN’s Company Database to build a full picture of global landscape of competitors
  2. Utilize LSN’s Investor Database to find investors and partners that are a fit for your stage of development and product set and aggregate a global target list
  3. Refine investor-centric marketing collateral (following the instructions of the Branding and Messaging class)
  4. Leverage your infrastructure to do email marketing campaigns and nurture leads in a CRM
  5. Start email and phone canvassing each day, supervised and mentored by LSN expert BD staff
  6. Set up intro phone calls and meetings
  7. Prepare for the upcoming RESI conference

Announcing RESI Asia Innovation Challenge Finalists

31 Oct

By Karen Deyo, Senior Investor Research Analyst, LSN

We are excited to announce the finalists in the Innovation Challenge at both RESI Shanghai, taking place on Tuesday, Nov. 12th and RESI Taipei, taking place on Thursday, Nov. 14th. These companies will present posters in the Exhibit Hall, where RESI attendees can see their innovative technologies and ‘invest’ their ‘RESI cash’ tokens to vote for their favorite companies. The three companies with the most ‘invested’ by the end of the day will win prizes.

In addition to presenting posters, for the first time, each company will also get an opportunity to pitch to a panel of investors and industry experts, who will ask questions and provide feedback. Below are the pitching schedules for the selected companies – make sure to stop by and watch these amazing companies pitch!

RESI Shanghai Innovation & Pitch Challenge

RESI Taipei Innovation & Pitch Challenge

What is Partnering? – The Importance of Partnering in the Life Sciences

31 Oct

By Lucy Parkinson, VP of Investor Research, LSN

At LSN, we talk a lot about life science partnering meetings: our goal is to make RESI Partnering as productive for our RESI attendees as possible. LSN founded RESI because we had learned that while there are many other partnering events in the life science world, the experience was often lacking and we thought we could substantially improve it (and we have). Partnering is so instinctive for us that we rarely stop to think about what partnering is, and why it’s so important in the life science sector in particular: you might say partnering is just in our DNA.

As we’ve brought RESI to Asia, we’ve learned about how Asia has a different style of doing business conferences, where partnering is much less widely known. We therefore wanted to make a ground-up introduction to life science partnering.

Why Partnering, Why In Life Science?

Partnering was originally driven by the needs of big pharma companies. These firms have an intense focus on developing their future pipelines, and this often means looking for external assets that they could license in to bolster their strategies as existing products move toward the end of patent life. Pharmas draw up specific maps of the technologies that they need, and have sophisticated teams that look externally for these assets.

The life sciences industry is as much a people business as it is a technology business. When a pharma company licenses an asset, that often means embarking on years of co-development work in which the pharma and the startup share resources and expertise to bring the product through clinical trials. It’s therefore essential to meet people face to face, get to know how they work, and learn to trust them. However, networking in a conference hall isn’t the best way to find the people who are developing those specific technologies that are needed.

Partnering events offered pharma BD staff a way to meet lots of drug development entrepreneurs in one place, by using an online system to receive meeting requests and select in advance who they wanted to connect with at the event. This offered much more efficiency than networking, and a much more personal connection than watching a startup give a pitch on a stage.

Since its origin, partnering events have also served other investors and life science players as well, such as CROs and other service providers who can use the events to connect with new customers who need their particular expertise.

What happens at a partnering event?

When you register for a partnering event like RESI, you will be added to an online meeting schedule system that you can use to plan your day.  You can use this system to send messages to other attendees and ask them to meet with you.  You will also receive messages from other attendees, and can decide whether to accept or decline their meeting requests.  In this way, every attendee manages their own schedule and decides for themself who they would like to meet.

If a meeting request is accepted, the system will find a time and location for the meeting.  The locations will be numbered tables or booths where you can sit down and talk to your meeting partner, usually for 30 minutes. It’s therefore possible to have in-depth conversations about your business with lots of people in one day.

If you have other plans throughout the day, such as a presentation or panel session you wish to attend, the partnering system will allow you to mark yourself as unavailable for meetings at those times.  Be sure to set your availability before you make any meeting requests.

How did RESI change partnering?

While partnering is generally more efficient than networking, it is still often hard to find meeting partners who are a good fit for your business. For example, if you are an entrepreneur developing a new cell therapy product in the cardiovascular space, it might be difficult to identify investors who are interested in this type of technology. You might inadvertently send requests to people who aren’t a relevant fit, and receive a poor return on your efforts. From the investor or pharma point of view, it can be very challenging to receive many unsuitable meeting requests at an event, and time-consuming to filter through them for good fits.

The other big challenge for entrepreneurs attending a partnering event is simply finding real investors who are ready to allocate. At many events, active investors are thin on the ground, and you might end up meeting someone who claims to be an ‘investor’ but is really just a broker or investment banker.

RESI’s key insights are thus: in life science, there are buyers (typically investors, big pharma and other corporations that invest strategically such as medical device corporations), and there are sellers (scientist-entrepreneurs and early stage companies). Good partnering depends on both of these sides having fully developed profiles that can be filtered to look for relevant fits.

The second key insight is that it takes a dedicated team to find investors, vet investors, invite them to the event, and profile their requirements. LSN’s Investor Research team is dedicated to speaking with investors and pharma/strategic investors worldwide and learning what they are looking for. Most RESI events have a 1:1 ratio of startups to investors, thereby maximizing an entreprenur’s chance of getting investor meetings.

The third key insight is that the life sciences industry is an extremely granular business. Everyone has their own niche of expertise and technological savvy, from antibodies to robotics to medical AI. In addition to technology type, stage of product development is also an extremely significant variable. There are some investors who specialize in making investments in preclinical or prototype-stage companies; meanwhile, others prefer to only invest after the company’s product has proven its clinical safety and/or efficacy. It’s therefore not enough to simply bring investors to an event, or to offer startups a chance to send messages to them. LSN’s Investor Research team prepopulate investor profiles with information on what the investor is looking for and what their criteria are, in order to help startups identify the investors who are truly a fit for them.

So how does that affect entrepreneurs?  It means you are more likely to meet the right people. It means that when you sit down across from an investor, you already know you have a good fit – they’re interested in technologies like yours, and they have money to invest in people like you. For hundreds of RESI attendees, these initial meetings have eventually led to receiving an investment.

As we bring RESI Partnering to Asia for the first time, we hope to continue this success and make many more new connections happen.

Video: The Redefining Early Stage Investments (RESI) Conference

31 Oct

By Nono Hu, Director of Marketing, LSN

The Redefining Early Stage Investments (RESI) Conference presents many great opportunities for life science entrepreneurs looking for investors. RESI offers entrepreneurs the opportunity to engage in 1-on-1 meetings – up to 16 scheduled 1-on-1’s in a day and many additional ad-hoc meetings!

Life Science Nation (LSN) isn’t just RESI though. This video provides an overview of how RESI fits together with LSN’s two other services, the LSN Investor Platform and LSN Company Platform, and also with Boston Innovation Capital (BIC), a registered broker dealer who is a wholly owned subsidiary of LSN.

Come learn about how attending RESI and utilizing our other services can help you find the investors you’re looking for in the video below! Also, be sure to register for RESI Asia for a chance to experience how RESI can help you make the connections you need to get the investment you need.

RESI Asia Partnering Launches Monday, October 28th

24 Oct

By Karen Deyo, Senior Investor Research Analyst, LSN

The partnering platform has always been one of the main differentiators of the RESI Conference. Powered by the LSN Investor Platform, the detailed investor profiles that allow companies to book one-on-one meetings with partners who are a fit for them streamlines the process and improves the quality of the meetings that take place at RESI. The partnering platform allows attendees to filter by sector, stage of development, indication, among other factors, to find only those investors and strategic partners who are looking for technologies like theirs. Once an attendee requests a meeting, and the recipient has accepted it, the partnering platform will automatically assign a time and a table for the meeting to take place. Starting on Monday, Oct. 28th, attendees of RESI Asia will be able to take advantage of this system to book up to 16 high-quality one-on-one meetings. If you are interested in learning tips on how to make the best use of the partnering platform, here are a few articles that can help:

Confirmed RESI Asia Investors

VIVA Biotech, Shanghai, China based CRO will be the Innovation Challenge Gold Sponsor for RESI

24 Oct

By Candice He, Global Investment Strategist, LSN

After supporting the RESI Conference Series with delegates and speakers for many years, VIVA Biotech has become a Gold Sponsor of RESI Shanghai and RESI San Francisco.  At RESI, you will be able to meet with VIVA’s delegation of elite portfolio companies, and with top expert speakers representing VIVA at RESI’s panels and pitch sessions. You will also have the opportunity to meet with VIVA during RESI’s cocktail party, where VIVA will present the awards for the RESI Innovation Challenge!  Finally, RESI Shanghai attendees will also have the opportunity to take a tour of VIVA Biotech’s incubator.  We hope you will join us and our sponsors and partners at RESI Shanghai.

About VIVA Biotech

Viva Biotech’s mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combing the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers’ needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of June 30, 2019, Viva Biotech had provided drug discovery services to 388 biotechnology and pharmaceutical customers worldwide, worked on over 1,000 independent drug targets, delivered over 11,000 independent protein structures, and incubated a total of 37 early stage R&D projects.

Supporting RESI Conferences for years, VIVA Biotech will be the Innovation Challenge Gold Sponsor for RESI Shanghai on Nov. 12th and RESI San Francisco on Nov. 14th